ArticleNature genetics2017
Genome-wide analyses identify common variants associated with macular telangiectasia type 2.
Article in Nature genetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Genome-wide meta-analysis identifies novel loci associated with age-related macular degeneration.Journal of human genetics · 2020Pooled it
- Macular Telangiectasia Type 2: A Case Series.Cureus · 2026Article
- Macular telangiectasia type 2: An update.The Journal of international medical research · 2026Review
- Convergent human genetic evidence implicates serine biosynthesis in diabetic peripheral neuropathy.medRxiv : the preprint server for health sciences · 2026Article
- Disease-associated microRNA, miR-9-2, regulates timing of retinal progenitor cell competence and maintenance of Müller glial identity.bioRxiv : the preprint server for biology · 2026Article
- Variant-to-gene mapping identifiesbioRxiv : the preprint server for biology · 2026Article
- Macular Telangiectasia Type 2: The Role of Optical Coherence Tomography and Management Options.Journal of clinical medicine · 2026Review
- Results from a Phase I Extension Study of Ciliary Neurotrophic Factor in Patients with Macular Telangiectasia Type 2.Ophthalmology science · 2026Article
- 1-deoxysphingolipids dysregulate membrane properties and cargo trafficking in the early secretory pathway.Cell chemical biology · 2026Article
- Progressive inner retinal neurodegeneration in non-proliferative macular telangiectasia type 2.The British journal of ophthalmology · 2025Article
- Genetic Background of Macular Telangiectasia Type 2.International journal of molecular sciences · 2025Review
- Serine supplementation suppresses hypoxia-induced pathological retinal angiogenesis.Theranostics · 2025Article
- Macular telangiectasia type 2 in a patient with Down syndrome: A possible association.American journal of ophthalmology case reports · 2024Article
- Cohort-based strategies as an in-house tool to evaluate and improve phenotyping robustness of LC-MS/MS lipidomics platforms.Analytical and bioanalytical chemistry · 2024Article
- ASCT2 is a major contributor to serine uptake in cancer cells.Cell reports · 2024Article
- High-throughput ultrastructural analysis of macular telangiectasia type 2.Frontiers in ophthalmology · 2024Article
- Unraveling the mysteries of macular telangiectasia 2: the intersection of philanthropy, multimodal imaging and molecular genetics. The 2022 founders lecture of the pan American vitreoretinal society.International journal of retina and vitreous · 2023Review
- New insights in the targets of action of dimethyl fumarate in endothelial cells: effects on energetic metabolism and serine synthesis in vitro and in vivo.Communications biology · 2023Article
- ASCT2 is the primary serine transporter in cancer cells.bioRxiv : the preprint server for biology · 2023Article
- Constructing and interpreting a large-scale variant effect map for an ultrarare disease gene: Comprehensive prediction of the functional impact of PSAT1 genotypes.PLoS genetics · 2023Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Idiopathic juxtafoveal retinal telangiectasis type 2 (macular telangiectasia type 2; MacTel) is a rare neurovascular degenerative retinal disease. To identify genetic susceptibility loci for MacTel, we performed a genome-wide association study (GWAS) with 476 cases and 1,733 controls of European ancestry. Genome-wide significant associations (P < 5 × 10
Indexed as
Identifiers
28250457What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.